Analysis of Clinicopathological Characteristics of Malignancy Patients with Membranous Nephropathy and Literature Review

References

• Ronco P, Beck L, Debiec H. et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69. doi:10.1038/s41572-021-00303-z
   PubMed Web of Science ®Google Scholar
• Li JN, Cui Z, Long JY, et al. Primary glomerular nephropathy among hospitalized patients in a national database in China. Nephrol Dial Transpl. 2018;33(12):2173–2181. doi:10.1093/ndt/gfy022
   PubMed Web of Science ®Google Scholar
• Qin Y, Zhao J, Wei X, et al. Distribution of pathological types and epidemiological characteristics based on kidney biopsy in Northwest China. Kidney Res Clin Pract. 2023;42(1):63–74. doi:10.23876/j.krcp.21.296
   PubMed Web of Science ®Google Scholar
• Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int. 1999;56(1):355–377. doi:10.1046/j.1523-1755.1999.00548.x
   PubMed Web of Science ®Google Scholar
• Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin. 2021;71(1):47–77. doi:10.3322/caac.21636
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276. 10.1016/j.kint.2021.05.021.
   PubMed Web of Science ®Google Scholar
• Yasuda I, Tokuyama H, Hashiguchi A, et al. Malignancy-associated membranous nephropathy with PLA2R double-positive for glomeruli and carcinoma. CEN Case Rep. 2021;10(2):281–286. doi:10.1007/s13730-020-00556-9
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Matsui I, Mano K, et al. Recurrent membranous nephropathy with a possible alteration in the etiology: a case report. BMC Nephrol 2021; 22(1):253. 10.1186/s12882-021-02457-0.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang L, Zhong W, Zheng K, Ye W, Wang M. Case report: THSD7A-positive membranous nephropathy caused by tislelizumab in a lung cancer patient. Front Immunol. 2021;12:619147. doi:10.3389/fimmu.2021.619147
   PubMed Web of Science ®Google Scholar
• Hoxha E, Wiech T, Stahl PR, et al. A mechanism for cancer-associated membranous nephropathy. N Engl J Med. 2016;374(20):1995–1996. 10.1056/NEJMc1511702.
   PubMed Web of Science ®Google Scholar
• Taguchi S, Koshikawa Y, Ohyama S, Miyachi H, Ozawa H, Asada H. Thrombospondin type-1 domain-containing 7A-associated membranous nephropathy after resection of rectal cancer: a case report. BMC Nephrol. 2019; 20(1):43. doi:10.1186/s12882-019-1236-y
   PubMedGoogle Scholar
• Hara S, Tsuji T, Fukasawa Y, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019;474(6):735–743. doi:10.1007/s00428-019-02558-0
   PubMed Web of Science ®Google Scholar
• Lin F, Zhang D, Chang J, et al. THSD7A-associated membranous nephropathy in a patient with neurofibromatosis type 1. Eur J Med Genet. 2018;61(2):84–88. doi:10.1016/j.ejmg.2017.10.014
   PubMed Web of Science ®Google Scholar
• Hoxha E, Beck LH, Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7a-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2017;28(2):520–531. doi:10.1681/asn.2016010050
   PubMed Web of Science ®Google Scholar
• Zhou S, Meng F, Yue S, Li H, Zhang L, Wang T. Backtracking cryptic recurrence of esophageal cancer from membranous nephropathy: the detection of glomerular NELL-1 and IgG4. Clin Kidney J Apr. 2023;16(4):756–759. doi:10.1093/ckj/sfac261
   PubMed Web of Science ®Google Scholar
• Caza TN, Hassen SI, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int Apr. 2021;99(4):967–976. doi:10.1016/j.kint.2020.07.039
   PubMed Web of Science ®Google Scholar
• Baker LW, Jimenez-Lopez J, Geiger XJ, Aslam N. Malignancy-associated membranous nephropathy with positive anti-PLA2R autoantibodies: coincidence or connection. Case Rep Nephrol Dial Sep-Dec. 2021;11(3):334–339. doi:10.1159/000520399
   PubMed Web of Science ®Google Scholar
• Morimoto N, Nagahama K, Tsuura Y, et al. Membranous nephropathy in a patient with pulmonary tuberculosis infection and lung adenocarcinoma: a case report. CEN Case Rep. 2022;11(1):126–133. doi:10.1007/s13730-021-00641-7
   PubMed Web of Science ®Google Scholar
• Hanset N, Aydin S, Demoulin N, et al. Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study. Am J Kidney Dis. 2020;76(5):624–635. doi:10.1053/j.ajkd.2020.04.013
   PubMed Web of Science ®Google Scholar
• Zappi S, Bernasconi L, Fischer I, et al. Lesson for the clinical nephrologist: thrombospondin type-1 domain-containing protein 7A-associated membranous nephropathy and Fanconi syndrome in a patient with a squamous cell lung cancer. J Nephrol. 2023;36(8):2395–2399. doi:10.1007/s40620-023-01630-y
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Chen D, et al. Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy. J Clin Pathol. 2019;72(10):705–711. doi:10.1136/jclinpath-2019-205852
   PubMed Web of Science ®Google Scholar
• Nickler M, Fischer I, Bernasconi L, et al. The unwelcome connection from lung cancer to glomeruli: a case report; proceedings of the SWISS MEDICAL WEEKLY. FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND: EMH SWISS MEDICAL PUBLISHERS LTD. 2020; 29S–29S.
   Google Scholar
• Ningning H, Lin F. Remission of refractory THSD7A-associated membranous nephropathy using rituximab: a case report. J Am Soc Nephrol. 2019;30(370):1.
   PubMedGoogle Scholar
• Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006;70(8):1510–1517. doi:10.1038/sj.ki.5001790
   PubMed Web of Science ®Google Scholar
• Lönnbro-Widgren J, Ebefors K, Mölne J, Nyström J, Haraldsson B. Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy. Clin Kidney J. 2015;8(4):433–439. doi:10.1093/ckj/sfv049
   PubMedGoogle Scholar
• Oliveira DB. Membranous nephropathy: an IgG4-mediated disease. Lancet. 1998;351(9103):9103):670–1. doi:10.1016/s0140-6736(97)04122-6
   Web of Science ®Google Scholar
• Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004;19(3):574–579. doi:10.1093/ndt/gfg616
   PubMed Web of Science ®Google Scholar
• Qu Z, Liu G, Li J, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant. 2012;27(5):1931–1937. doi:10.1093/ndt/gfr534
   PubMed Web of Science ®Google Scholar
• Hoxha E, Kneißler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012;82(7):797–804. doi:10.1038/ki.2012.209
   PubMed Web of Science ®Google Scholar
• Ai S, Yan X, Zhao X, et al. Malignancy-associated membranous nephropathy: focus on diagnosis and treatment. J Nephrol. 2023;36(8):2355–2363. doi:10.1007/s40620-023-01751-4
   PubMed Web of Science ®Google Scholar
• Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A 2. Annu Rev Biochem. 2008;77(1):495–520. doi:10.1146/annurev.biochem.76.062405.154007
   PubMedGoogle Scholar
• von Haxthausen F, Reinhard L, Pinnschmidt HO, et al. Antigen-specific igg subclasses in primary and malignancy-associated membranous nephropathy. Front Immunol. 2018;9:3035. doi:10.3389/fimmu.2018.03035
   PubMed Web of Science ®Google Scholar
• Qu Z, Liu G, Li J, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant. 2012;27(5):1931–1937. doi:10.1093/ndt/gfr534
   PubMed Web of Science ®Google Scholar
• Stahl PR, Hoxha E, Wiech T, Schröder C, Simon R, Stahl RA. THSD7A expression in human cancer. Genes Chromosomes Cancer Apr. 2017;56(4):314–327. doi:10.1002/gcc.22440
   PubMed Web of Science ®Google Scholar
• Wang CH, Su PT, Du XY, et al. Thrombospondin type I domain containing 7A (THSD7A) mediates endothelial cell migration and tube formation. J Cell Physiol. 2010;222(3):685–694. doi:10.1002/jcp.21990
   PubMed Web of Science ®Google Scholar